ATTC network education day: CAR T clinical trials in autoimmune diseases

This education day focuses on CAR T clinical trials within the field of autoimmune conditions, bringing together a range of expert speakers from across Scotland and the UK.

Advancing site readiness for CAR-T delivery in autoimmune indications | Case studies with practical insights

This 90-minute session will feature four case study presentations from experienced clinical sites, highlighting how they have developed local capability and infrastructure to support CAR T trials in autoimmune indications.

Driving ATMP clinical trials through training and education: Progress and next steps for a UK ATMP training programme

Discover how the ATTC network is supporting training and education of NHS staff for advanced therapy trials.

Evaluation of the Patient Referral Pathways for Gene Therapy and CAR-T in the UK

Cell and Gene Therapy UK Ecosystem : "2032 Crystal Ball"

Only slides are available There is a very strong global optimism regarding the immediate future of cell and gene therapy and the UK Ecosystem generally is ‘punching above its weight’. Where will the UK feature over the next 10 years and what will be needed to optimise our contribution to transformative medical treatment and economic benefit? This webinar addresses critical…

Patient and Public Engagement in the development of cell and gene therapies – why it matters and how to engage with people

Only slides from the event are available Involving patients in the development of ATMPs is a key part of improving outcomes for patients. This webinar explores the rationale around why patient and public engagement is essential in the development of new therapies, focusing on the specific challenges and needs for cell and gene therapy and the benefits to patient and…

UK Advanced Therapies Remit

Only slides are available. The presentation focuses on the impact that the work of UK Advanced Therapies has had including a number of case studies.

Standardisation of procurement of starting materials by apheresis for advanced therapies

Only slides from the event are available The quality and safety of Advanced Therapy Medicinal Products (ATMPs) are contingent on that of their starting materials, particularly where these are substance of human origin such as mononuclear cells (MNCs) procured by apheresis. Across the UK there are over 50 Clinical Apheresis Units (CAUs) operating under a Human Tissue Authority (HTA) collecting starting material…

Building the UK ecosystem for the delivery of ATMPs

Only slides are available   It is well known that there are substantial challenges for the development and clinical supply of Advanced Therapy Medicinal products (ATMP).  These  span many different themes: complex regulatory pathways; unfamiliar clinical procurement practices; novel biology; limited data to justify reimbursement; high cost of goods, to name just a few. As such it is important for…

Micro-costing toolkit for advanced therapy medicinal products (ATMPs) - Sophie Hughes